{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T23:54:27Z","timestamp":1768780467031,"version":"3.49.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.lfs.2019.05.051","type":"journal-article","created":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T02:31:51Z","timestamp":1558405911000},"page":"19-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Effect of ipragliflozin, an SGLT2 inhibitor, on cardiac histopathological changes in a non-diabetic rat model of cardiomyopathy"],"prefix":"10.1016","volume":"230","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4235-083X","authenticated-orcid":false,"given":"Toshiyuki","family":"Takasu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoji","family":"Takakura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2019.05.051_bb0005","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2147\/DDDT.S50773","article-title":"Update on developments with SGLT2 inhibitors in the management of type 2 diabetes","volume":"8","author":"Nauck","year":"2014","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.lfs.2019.05.051_bb0010","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2019.05.051_bb0015","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2019.05.051_bb0020","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2019.05.051_bb0025","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/ejhf.933","article-title":"The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors","volume":"19","author":"Butler","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.lfs.2019.05.051_bb0030","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lfs.2019.05.051_bb0035","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.lfs.2019.05.051_bb0040","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s00125-016-3956-x","article-title":"SGLT2 inhibition and cardiovascular events: why did EMPA-REG outcomes surprise and what were the likely mechanisms?","volume":"59","author":"Sattar","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.lfs.2019.05.051_bb0045","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.lfs.2019.05.051_bb0050","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.kint.2015.12.038","article-title":"Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis","volume":"89","author":"Rajasekeran","year":"2016","journal-title":"Kidney Int."},{"key":"10.1016\/j.lfs.2019.05.051_bb0055","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11010-017-3018-9","article-title":"Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial?","volume":"433","author":"Shi","year":"2017","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.lfs.2019.05.051_bb0060","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1038\/nutd.2010.1","article-title":"Characterization of a new animal model of metabolic syndrome: the DahlS.Z-Lepr(fa)\/Lepr(fa) rat","volume":"1","author":"Hattori","year":"2011","journal-title":"Nutr. Diabetes"},{"key":"10.1016\/j.lfs.2019.05.051_bb0065","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/hr.2011.157","article-title":"Cardiac remodeling and diastolic dysfunction in DahlS.Z-Lepr(fa)\/Lepr(fa) rats: a new animal model of metabolic syndrome","volume":"35","author":"Murase","year":"2012","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.lfs.2019.05.051_bb0070","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00210-011-0713-z","article-title":"Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo","volume":"385","author":"Tahara","year":"2012","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.lfs.2019.05.051_bb0075","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1254\/jphs.12089FP","article-title":"Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice","volume":"120","author":"Tahara","year":"2012","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.lfs.2019.05.051_bb0080","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/jphp.12223","article-title":"Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats","volume":"66","author":"Tahara","year":"2014","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.lfs.2019.05.051_bb0085","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.lfs.2016.01.042","article-title":"Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats","volume":"147","author":"Takakura","year":"2016","journal-title":"Life Sci."},{"key":"10.1016\/j.lfs.2019.05.051_bb0090","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1248\/bpb.b17-01007","article-title":"Protective effect of Ipragliflozin on pancreatic islet cells in obese type 2 diabetic db\/db mice","volume":"41","author":"Takasu","year":"2018","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.lfs.2019.05.051_bb0095","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejphar.2014.01.040","article-title":"SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats","volume":"727","author":"Yokono","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.lfs.2019.05.051_bb0100","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejphar.2015.02.009","article-title":"Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats","volume":"754","author":"Hayashizaki-Someya","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.lfs.2019.05.051_bb0105","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/406394","article-title":"Effect of repetitive glucose spike and hypoglycaemia on atherosclerosis and death rate in Apo E-deficient mice","volume":"2015","author":"Nakajima","year":"2015","journal-title":"Int. J. Endocrinol."},{"key":"10.1016\/j.lfs.2019.05.051_bb0110","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-12106-y","article-title":"Time-dependent effects of ipragliflozin on behaviour and energy homeostasis in normal and type 2 diabetic rats: continuous glucose telemetry analysis","volume":"7","author":"Iuchi","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2019.05.051_bb0115","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00395-003-0401-3","volume":"98","author":"Reffelmann","year":"2003","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.lfs.2019.05.051_bb0120","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1161\/HYPERTENSIONAHA.111.180976","article-title":"Effects of estrogen on cardiovascular injury in ovariectomized female DahlS.Z-Lepr(fa)\/Lepr(fa) rats as a new animal model of metabolic syndrome","volume":"59","author":"Murase","year":"2012","journal-title":"Hypertension"},{"issue":"Suppl. 6","key":"10.1016\/j.lfs.2019.05.051_bb0125","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1097\/00005344-199312050-00008","article-title":"Oxygen radical scavengers and renal protection by indapamide diuretic in salt-induced hypertension of Dahl strain rats","volume":"22","author":"Uehara","year":"1993","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.lfs.2019.05.051_bb0130","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1161\/HYPERTENSIONAHA.113.02093","article-title":"Calorie restriction attenuates cardiac remodeling and diastolic dysfunction in a rat model of metabolic syndrome","volume":"62","author":"Takatsu","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.lfs.2019.05.051_bb0135","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001312","article-title":"Dietary salt restriction improves cardiac and adipose tissue pathology independently of obesity in a rat model of metabolic syndrome","volume":"3","author":"Hattori","year":"2014","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.lfs.2019.05.051_bb0140","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/joim.12756","article-title":"Biomarkers for heart failure: small molecules with high clinical relevance","volume":"283","author":"Magnussen","year":"2018","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.lfs.2019.05.051_bb0145","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/1440-1681.12725","article-title":"Effect of a selective SGLT2 inhibitor, luseogliflozin, on circadian rhythm of sympathetic nervous function and locomotor activities in metabolic syndrome rats","volume":"44","author":"Rahman","year":"2017","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.lfs.2019.05.051_bb0150","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3389\/fendo.2018.00421","article-title":"The effects of sodium-glucose cotransporter 2 inhibitors on sympathetic nervous activity","volume":"9","author":"Wan","year":"2018","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.lfs.2019.05.051_bb0155","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1111\/dom.13229","article-title":"Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis","volume":"20","author":"Packer","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.lfs.2019.05.051_bb0160","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.jacc.2008.05.060","article-title":"Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease","volume":"52","author":"Martin","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.lfs.2019.05.051_bb0165","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1248\/bpb.b16-00964","article-title":"The sodium glucose cotransporter 2 inhibitor ipragliflozin promotes preferential loss of fat mass in non-obese diabetic Goto-Kakizaki rats","volume":"40","author":"Takasu","year":"2017","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.lfs.2019.05.051_bb0170","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fcvm.2016.00043","article-title":"Glycemic control with Ipragliflozin, a novel selective SGLT2 inhibitor, ameliorated endothelial dysfunction in streptozotocin-induced diabetic mouse","volume":"3","author":"Salim","year":"2016","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.lfs.2019.05.051_bb0175","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12933-018-0708-x","article-title":"SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice","volume":"17","author":"Lee","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.lfs.2019.05.051_bb0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112394","article-title":"The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity","volume":"9","author":"Oelze","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2019.05.051_bb0185","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.redox.2017.06.009","article-title":"The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats","volume":"13","author":"Steven","year":"2017","journal-title":"Redox Biol."},{"key":"10.1016\/j.lfs.2019.05.051_bb0190","doi-asserted-by":"crossref","first-page":"10","DOI":"10.12998\/wjcc.v3.i1.10","article-title":"Evaluation of chronic kidney disease in chronic heart failure: from biomarkers to arterial renal resistances","volume":"3","author":"Iacoviello","year":"2015","journal-title":"World J. Clin. Cases"},{"key":"10.1016\/j.lfs.2019.05.051_bb0195","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/clc.23054","article-title":"The emerging role of novel antihyperglycemic agents in the treatment of heart failure and diabetes: a focus on cardiorenal outcomes","volume":"41","author":"McHugh","year":"2018","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.lfs.2019.05.051_bb0200","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/ndt\/gfq136","article-title":"Definition and classification of cardio-renal syndromes: workgroup statements from the 7th ADQI consensus conference","volume":"25","author":"House","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.lfs.2019.05.051_bb0205","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/1479164118783756","article-title":"Effects of sodium glucose co-transporter 2 inhibitors on the kidney","volume":"15","author":"de Albuquerque Rocha","year":"2018","journal-title":"Diab. Vasc. Dis. Res."},{"key":"10.1016\/j.lfs.2019.05.051_bb0210","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1152\/ajpregu.00357.2011","article-title":"Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat","volume":"302","author":"Thomson","year":"2012","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.lfs.2019.05.051_bb0215","doi-asserted-by":"crossref","first-page":"F1406","DOI":"10.1152\/ajprenal.00384.2017","article-title":"Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease","volume":"315","author":"Leon Jimenez","year":"2018","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.lfs.2019.05.051_bb0220","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.pharmthera.2013.10.007","article-title":"Small and large animal models in cardiac contraction research: advantages and disadvantages","volume":"141","author":"Milani-Nejad","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.lfs.2019.05.051_bb0225","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000435947","article-title":"Heart rate, life expectancy and the cardiovascular system: therapeutic considerations","volume":"132","author":"Boudoulas","year":"2015","journal-title":"Cardiology"}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320519304072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320519304072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T20:21:07Z","timestamp":1758399667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320519304072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":45,"alternative-id":["S0024320519304072"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2019.05.051","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of ipragliflozin, an SGLT2 inhibitor, on cardiac histopathological changes in a non-diabetic rat model of cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2019.05.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}